Therapeutic drug monitoring of liposomal amphotericin B in children. Are we there yet? A systematic review
Open Access
- 22 January 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (4) , 703-711
Abstract
Therapeutic drug monitoring (TDM) is a tool that supports personalized dosing, but its role for liposomal amphotericin B (L-amb) is unclear. This systematic review assessed the evidence for L-amb TDM in children. To evaluate the concentration–efficacy relationship, concentration–toxicity relationship and pharmacokinetic/pharmacodynamic (PK/PD) variability of L-amb in children. We systematically reviewed PubMed and Embase databases following PRISMA guidelines. Eligible studies included L-amb PK/PD studies in children aged 0–18 years. Review articles, case series of 600 mg·h/L for nephrotoxicity. L-amb doses of 2.5–10 mg/kg/day were reported to achieve Cmax/MIC > 25 using an MIC of 1 mg/L. While significant PK variability was observed in children, evidence to support routine L-amb TDM was limited. Further studies on efficacy and toxicity benefits are required before routine TDM of L-amb can be recommended.Keywords
Funding Information
- Australian Government (RTP) Scholarship
This publication has 45 references indexed in Scilit:
- Antifungal Therapeutic Drug Monitoring: Established and Emerging IndicationsAntimicrobial Agents and Chemotherapy, 2009
- Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus CriteriaClinical Infectious Diseases, 2008
- Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)Clinical Infectious Diseases, 2007
- How to use medicines in children: Principles of paediatric clinical pharmacologyJournal of Paediatrics and Child Health, 2007
- Population Pharmacokinetics of Liposomal Amphotericin B in Pediatric Patients with Malignant DiseasesAntimicrobial Agents and Chemotherapy, 2006
- High-Dose Weekly AmBisome Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic StudyTransplantation and Cellular Therapy, 2006
- Pharmacokinetic-Pharmacodynamic Comparison of Amphotericin B (AMB) and Two Lipid-Associated AMB Preparations, Liposomal AMB and AMB Lipid Complex, in Murine Candidiasis ModelsAntimicrobial Agents and Chemotherapy, 2006
- Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected withAspergillusSpecies and Other Filamentous Fungi: Maximum Tolerated Dose StudyAntimicrobial Agents and Chemotherapy, 2001
- Correlates of acute renal failure in patients receiving parenteral amphotericin BKidney International, 2001
- Pharmacodynamics of Amphotericin B in a Neutropenic-Mouse Disseminated-Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2001